

CURRICULUM VITAE

CIANCIO ALESSIA. M.D., PhD

Working address: Department of Gastroenterology,
Città della Salute e delle Scienza di Torino (Molinette),
Ambulatorio di GastroEpatologia Sperimentazioni Cliniche Epatiti Virali
corso Bramante 88 - 10126 Torino

ORCID: [orcid.org/ 0000-0003-4188-0609](https://orcid.org/0000-0003-4188-0609)

- **Born:** in Pinerolo, Turin, Italy, May 17, 1969
- **Family:** Married with two kids

EDUCATION

- High School Degree in July 1988, at scientific liceum “M. Curie” in Pinerolo.
- M.D., magna cum laude, on October 25, 1994 at the 'University of Turin, discussing a thesis entitled “ Infectious complications after liver transplantation (OLT): bacteria and viral infections; morbidity and risk in immunodeficient patient”.
- Licensed to medical practice (Italy) at the University of Turin School of Medicine, June 1995. Chartered in the Italian Medical Register with N°17556 and authorized as Medical Doctor from June 1995.
- Undergraduate training at the Department of Gastroenterology, Hospital “S. Giovanni Battista di Torino” (Molinette) directed by Prof. G. Verme, November 1992 to October 1994.
- Post-graduate training at the Department of Gastroenterology, Hospital “S. Giovanni Battista di Torino” (Molinette) directed by Prof. G. Verme, October 1994 to October 1995.
- Research and clinical training from November 1995 to August 2006 , as a postgraduate specialist doctor at Department of Gastroenterology, Hospital “S. Giovanni Battista di Torino” (Molinette) directed by Prof. M. Rizzetto, working in the ward, in the liver transplant ambulatory and in Endoscopy Digestive Service.
- Postgraduate Speciality School in Gastroenterology and Digestive Endoscopy , magna cum laude, at the University of Turin discussing a thesis on “ Manganese concentration in advanced liver disease” on October 1999
- Research and clinical training during summer 1999 and March 2000, as a visiting scientist in Génève at the Department of Gastroenterology, Hopital Universitaire Cantonal de Génève directed by Prof. F. Negro, were she contribute to the sequencing of serum samples from patients underwent to liver transplant for HBV cirrhosis and treated with Lamivudine. During this research she identified a new mutation in the pre-s/s region of the virus.
- Research and clinical training from June 2001 to January 2003, as a visiting Scientist at the Division of Molecular Virology and Immunology, Georgetown University, School of Medicine, Washington DC (Director. Prof JL. Gerin) where she studied the virological profiles of patients with chronic hepatitis B, anti-e positive treated with Lamivudine. During this study she identified two polimorfisms predictive of response to Lamivudine therapy. During her period in the US she

collaborated in two different projects: the HCV-RNA quantification by Real Time assay on cell culture infected with HCV and microarrays assay for the evaluation of gene patterns expression in woodchuck infected with HBV.

- PhD in “Medical Physiopathology” at the university of Turin, on 19 th January 2004 .
- Research associate at the Department of Gastroenterology, Hospital “S. Giovanni Battista di Torino” (Molinette) and Turin University from October 2006 to June 2019
- Associate Professor of Gastroenterology, Division of Gastroenterology and Hepatology Department of Medical Sciences University of Torino from July 2019 until now
- Several years experience (from 1998) as Investigator in International (phase II, III and IV) and local clinical trials conducted under ICH-GCP procedures in antiviral therapy and viral chronic hepatitis HBV, HDV and HCV treatment.
- GCP training during Investigator Meetings or Initiation visits.

Teaching activity at University of Torino

- Gastroenterology, Medicine and Surgery, San Luigi Gonzaga University Hospital , English Degree - from 2018 until now
- Gastroenterologia, Medicina e Chirurgia, Città della Salute e della Scienza di Torino , Laurea in italiano - from 2015 until now
- Gastroenterologia, corso integrato “Infermieristica Clinica in Area Medica” corso di Laurea in “Scienze Infermieristiche” di Asti, from 2009 until now
- Gastroenterologia, corso integrato “Infermieristica Clinica in Area Medica” corso di Laurea in “Scienze Infermieristiche” di Ivrea, from 2010 until now
- Gastroenterologia, corso integrato “Infermieristica Clinica in Area Medica” corso di Laurea in “Scienze Infermieristiche” di Aosta, from 2013 until now
- Gastroenterologia, corso di Laurea in “Fisioterapia” di Torino, from 2018 until now
- Gastroenterologia, Scuola di Specializzazione in Gastroenterologia, sede di Torino from 2015 until now
- Gastroenterologia, Scuola di Specializzazione in Scienze della Nutrizione, sede di Torino from 2015 until now

REFERENCES

1. Actis G.C., Lagget M., Ciancio A., Rocca G., Tomasini C., Puiatti P., Verme G. "Recurrent sweet's syndrome in reactivated Crohn's disease". *J. Clin. Gastroenterol* 1995; 21 (4): 317-9
2. Debernardi-Venon W., Brunello F., Gubetta L., Lavezzo B., Gastaldi P., Pasquero P., Ciancio A., Marzano A., Salizzoni M., Rizzetto M. "Epithelioid Hemangioendotelioma of the liver: report of a case treated by orthotopic liver transplantation (OLT)." *The Italian Journal of Gastroenterology* 1996; 28 (1):28-30
3. Rosina F., Alaria P., Castelli S., Dirindin N., Rocca G., Actis G.C., Borelli R., Ciancio A., Debernardi-Venon W., Fornasiera S., Lavezzo B., Lagget M., Martinotti R., Marzano A., Ottobrelli A., Sostegni R., Rizzetto M., Verme G. "Effect of patient characteristics on hospital for cirrhosis: implications for the disease-related group (DRG) reimbursement system." *Ital J. Gastroenterol* 1996; 28:401-405.
4. Rocca G., Ricci E., Ribotto M., Sostegni R., Fiorentini M.T., Lagget M., Ottobrelli A., Astegiano M., Ciancio A., Pera A., Rizzetto M. "Le complicanze sistemiche delle urgenze gastrointestinali. Criteri di valutazione implicazioni terapeutiche e prognostiche." *Giornale di Gastroenterologia* 1996; Vol 1 N° 3 p 115-125.
5. Mattalia A., Lutting B., Leung PS, Bauducci M., Worman H., Ciancio A., Rosina F., Coppel R.L., Manns M., Rizzetto M., Gershwin E. "Persistence of autoantibodies against recombinant mitochondrial and nuclear pore proteins after orthotopic liver transplantation for primary biliary cirrhosis." *Journal of autoimmunity* 1997; 10:491-497.
6. Actis G.C., Ciancio A., Lagget M., Marzano A., Ottobrelli A., Torrani Cerenzia M.R., Volpes R., Rizzetto M. e Verme G. "La ciclosporina nel trattamento della rettocolite ulcerosa refrattaria al cortisone. Risultati dello studio Torino 1990-1997". *Minerva Gastroenterol Dietol* 1998;44: 163-166.
7. Lagget M., Marzano A., Actis G.C., Leone N., Ciancio A., Salizzoni M., Rizzetto M. "Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients". *Transplant Proc.*, 1998; 30:1863-1864.
8. Rocca G., David E., Volpes R., Smedile A., Debernardi-Venon W., Ciancio A., Salizzoni M., Rizzetto M. "Hepatitis C virus infection in the etiology of ductopenia and ductopenic rejection (vanishing bile duct syndrome) after liver transplantation.
9. Veltri A, Grosso M, Martina MC, Ciancio A, David E, Salizzoni M, Soldano U, Galli J, Fava C. Effect of preoperative radiological treatment of hepatocellular carcinoma before liver transplantation: a retrospective study. *Cardiovasc Intervent Radiol.* 1998;21:393-8.
10. Saracco G., Ciancio A., Ghisetti V., Rocca G., Cariti G., Andreoni M., Tabone M., Roffi L., Calleri G., Ballarè M., Minoli G., Sartori M., Tappero GF., Traverso A., Poggio A., Orani AM., Maggi G., Di Napoli A., Arrigoni A., Rizzetto M. "Treatment with Interferon alfa-2b of naive non-cirrhotic patients with chronic hepatitis C according to viremia and genotype. Results of a randomised multicentric study. *Eur J Gastroenterol Hepatol.* 2001;13:149-55.
11. Pellicano R, Ponzetto A, Astegiano M, Smedile A, Saracco G, Durazzo M, Balzola F, Berrutti M, Lavezzo B, Ponti V, Morgando A, Ciancio A, Rizzetto M, Palmas F. Gastroenterologists in ambulatory care. The experience in Turin in the year 2000. *Minerva Med.* 2001;92:79-83.
12. Saracco G., Ciancio A., Olivero A., Smedile A., Roffi L., Croce G., Colletta C., Cariti G., Andreoni M., Biglino A., Calleri G., Maggi G., Tappero GF., Orsi PG., Terreni N., Macor A., Di Napoli A., Rinaldi E., Ciccone

- G., Rizzetto M. "A randomised 4-ARM multicentre study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone." *Hepatology*. 2001;34:133-8.
13. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, Gentilcore E, Piantino P, Barbui AM, David E, Negro F, Rizzetto M. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. *J Hepatol*. 2001;34:903-10.
 14. Marzano A, Ciancio A, Salizzoni M, Rizzetto M, Negro F. Hepatitis B virus subtypes and lamivudine resistance. *Lancet*. 2001;358:153-4.
 15. Masia G, Ingianni A, Demelia L, Faa G, Manconi PE, Pilleri G, Ciancio A, Rizzetto M, Coppola RC. TT virus infection in Italy: prevalence and genotypes in healthy subjects, viral liver diseases and asymptomatic infections by parenterally transmitted viruses. *J Viral Hepat*. 2001;8:384-90.
 16. Ciancio A, Marchet A, Saracco G, Carucci P, Lavezzo B, Leotta D, Capellero B, Nobili M, Smedile A, Rizzetto M. Spectral electroencephalogram analysis in hepatic encephalopathy and liver transplantation. *Liver Transpl*. 2002;8:630-5.
 17. Saracco G, Olivero A, Ciancio A, Carezzi S, Smedile A, Cariti G, Andreoni M, Orsi PG, Biglino A, Tabone M, Roffi L, Croce G, Manca A, Tappero G, Ciccone G, Rizzetto M. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. *Hepatology*. 2002;36:959-66.
 18. Saracco G., Olivero A, Ciancio A. Therapy of chronic hepatitis C: a critical review. *Curr Drug Targets Infect Disord*. 2003;3:25-32.
 19. Ciancio A, Smedile A, Rizzetto M, Lagget M, JL Gerin, B.Korba. Identification of HBV-DNA sequences that are predictive of response to Lamivudine Therapy. *Hepatology* 2004; 39; 1:64-73.
 20. Ciancio A, Manzini P, Castagno F, D'Antico S, Reynaudo P, Coucourde L, Ciccone G, Del Piano M, Ballare M, Peyre S, Rizzi R, Barletti C, Bruno M, Caronna S, Carucci P, Venon Wde B, De Angelis C, Morgando A, Musso A, Repici A, Rizzetto M, Saracco G. Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus. *Ann Intern Med*. 2005;142: 903-909.
 21. Niro GA, Ciancio A, Tillman HL, Lagget M, Olivero A, Perri F, Fontana R, Little N, Campbell F, Smedile A, Manns MP, Andriulli A, Rizzetto M. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. *Aliment Pharmacol Ther*. 2005;22:227-32.
 22. A. Ciancio, A. Smedile, C. Giordanino, C. Colletta, G. Croce, M. Pozzi, G. Cariti, A. Macor, A. Biglino, A. Di Napoli, GF Tappero, M. Andreoni, A. Manca, G. Prandi, G. Calleri, PG Orsi, G. Ciccone, M. Rizzetto, G. Saracco Long-term follow-up of previous hepatitis c virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured ? *Am J Gastroenterol* 2006 101: 1811-1816
 23. Olivero A, Ciancio A, Abate ML, Gaia S, Smedile A, Rizzetto M. Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations. *J Viral Hepat*. 2006;13:355-62.
 24. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, Stanzone M, David E, Brancaccio G, Fontana R, Perri F, Andriulli A, Rizzetto M. Pegylated interferon alpha-2b as monotherapy or in combination

with ribavirin in chronic hepatitis delta. *Hepatology*. 2006;44:713-20.

25. A. Ciancio, A. Picciotto, C. Giordanino, A. Smedile, M. Tabone, A. Manca, G. Marengo, P. Garbagnoli, M. Andreoni, G. Cariti, G. Calleri, M. Sartori, S. Cusumano, A. Grasso, R. Rizzi, M. Gallo, M. Basso, M. Anselmo, G. Percario, G. Ciccone, M. Rizzetto, G. Saracco A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. *Aliment Pharmacol Ther* 2006; 24: 1079-1086
26. Pellicano R, Bonardi R, Smedile A, Saracco G, Ponzetto A, Lagget M, Morgando A, Balzola F, Bruno M, Marzano A, Ponti V, Debernardi Venon W, Ciancio A, Rizzetto M, Astegiano M. Gastroenterology outpatient clinic of the Molinette Hospital (Turin, Italy): the 2003-2006 report. *Minerva Med*. 2007; 98:19-23.
27. Berrutti M, Ciancio A, Smedile A, Brunello F, Bonardi R, Pellicano R, Astegiano M, Sapone N, Touscoz GA, Rizzetto M. Assessment of liver fibrosis in the clinical setting: something is changing? *Minerva Gastroenterol Dietol*. 2007; 53:111-4.
28. Camerini R, Ciancio A, De Rosa A, Rizzetto M. Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C. *Ann N Y Acad Sci*. 2007;1112:368-74.
29. Rizzetto M, Ciancio A. Chronic HBV related liver disease. *Mol Aspects Med*. 2008;29:72-84.
30. Pittaluga F, Allice T, Abate ML, Ciancio A, Cerutti F, Varetto S, Colucci G, Smedile A, Ghisetti V. Clinical evaluation of the COBAS Amplipretrade mark/COBAS TaqMantrade mark for HCV RNA quantitation in comparison with the branched-DNA assay. *J Med Virol*. 2008;80:254-60.
31. Mangia A, Burra P, Ciancio A, Fagioli S, Guido M, Picciotto A, Fabrizi F. Hepatitis C infection in patients with chronic kidney disease. *Int J Artif Organs*. 2008;31:15-33.
32. Pellicano R, Puglisi G, Ciancio A, Balzola F, Saracco G, Ciccone G, Baldi I, Abate ML, Smedile A, Rizzetto M. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection? *J. Med Virol*. 2008;80:628-631
33. Giordanino C, Bugianesi E, Smedile A, Ciancio A, Abate ML, Olivero A, Pellicano R, Cassader M, Gambino R, Bo S, Ciccone G, Rizzetto M, Saracco G. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. *Am J Gastroenterol*. 2008; 103:2481-2487
34. Stroffolini T, Almasio PL, Sagnelli E, Mele A, Gaeta GB; Italian Hospitals' Collaborating Group. Evolving clinical landscape of chronic hepatitis B: a multicenter italian study. *J Med Virol* 2009; 81: 1999-2006
35. Ciancio A and Rizzetto M. Thymalfasin in the treatment of hepatitis B and C. *NYAS* 2010; 1194: 141 – 146
36. Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, Valvano MR, Abate ML, Gioffreda D, Caviglia GP, Rizzetto M, Andriulli A. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. *J Hepatol* 2010; 53: 834-840.
37. Vanni E, Actis GC, Ciancio A, Pellicano R, Abate ML, Touscoz GA, Smedile A, Rizzetto M. Practical out-patient management of autoimmune hepatitis. *Panminerva Med* 2010; 52: 265

38. Ciancio A, Rizzetto M. Peg Interferon for the treatment of hepatitis D. *Nat Rev Gastroenterol Hepatol*. 2011, 8:304-6
39. Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. *Biomed Pharmacother*. 2011;65:303-6.
40. D'Avolio A, Ciancio A, Siccardi M, Baietto L, Simiele M, Cariti G, Calcagno A, Smedile A, Cusato J, Bonora S, Rizzetto M, Di Perri G. Ribavirin pharmacokinetics and IL28B plus CYP27B1 SNPs as predictors of response to Peg-IFN/RBV treatment in HCV 1/4 infected patients *Hepatology* 2011; 54:2278-9
41. Ciancio A, Andreone P, Kaiser, Mangia A, Milella M, Solà R, Pol S, Tsianos E, De Rosa A, Camerini R, McBeath R, Rizzetto M. Thymosin alpha-1 in combination with Peg-Interferon alfa-2a and Ribavirin for the therapy of chronic hepatitis C non-responsive to the combination of IFN and Ribavirin; an adjuvant role? *Hepatology J Viral Hepat*. 2012 (19): 52-59
42. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Baietto L, Simiele M, Marucco DA, Cariti G, Calcagno A, de Requena DG, Sciandra M, Cusato J, Troshina G, Bonora S, Rizzetto M, Di Perri G. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associated anemia in patients receiving standard anti-HCV treatment. *Ther Drug Monit*. 2012;34:165-70.
43. Rizzetto M, Ciancio A. Epidemiology of hepatitis D. *Semin Liver Dis*. 2012; 32:211-9.
44. Marengo A, Bitetto D, D'Avolio A, Ciancio A, Fabris C, Marietti M, Toniutto P, Di Perri G, Rizzetto M, Marzano A Clinical and virologic response to entecavir in HBV related chronic hepatitis or cirrhosis: data from the clinical practice in a single centre cohort. *Antivir Ther*. 2013; 18:87-94
45. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Simiele M, Cusato J, Baietto L, Marucco DA, Cariti G, Calcagno A, Gonzalez de Requena D, Sciandra M, Troshina G, Caviglia GP, Bonora S, Rizzetto M, Di Perri G. Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. *Ther Drug Monit*. 2012; 34:722-8
46. Caviglia GP, Abate ML, Manzini P, Danielle F, Ciancio A, Rosso C, Olivero A, Pellicano R, Touscoz GA, Smedile A, Rizzetto M. Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy. *Hepat Mon*. 2012;12:e7292
47. Wedemeyer H, Jensen D, Herring R Jr, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J, Ipe D, Munson ML, Chen YC, Najera I, Thommes J; PROPEL Investigators. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. *Hepatology*. 2013;58:524-37.
48. Italian Association for the Study of the Liver (AISF); AISF Expert Panel; AISF Coordinating Committee, Bolondi L, Cillo U, Colombo M, Craxi A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. *Dig Liver Dis*. 2013;45:712-23.
49. Gaia S, Olivero A, Smedile A, Ruella M, Abate ML, Fadda M, Rolle E, Omedè P, Bondesan P, Passera R, Risso A, Aragno M, Marzano A, Ciancio A, Rizzetto M, Tarella C. Multiple courses of G-CSF in patients

with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluation. *Hepatology*. 2013;7:1075-83

50. D'Avolio A, De Nicolò A, Cusato J, Ciancio A, Boglione L, Strona S, Cariti G, Troshina G, Caviglia GP, Smedile A, Rizzetto M, Di Perri G. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. *Antiviral Res.* 2013;100:114-9.

51. Caviglia GP, Ciancio A, Rosso C, Abate ML, Olivero A, Pellicano R, Touscoz GA, Smedile A, Rizzetto M. Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, ¹³C-aminopyrine breath test and cytokeratin 18 fragment. *Ann Hepatol.* 2013 Jan-2014 Feb;13(1):91-7.

52. Italian Association for the Study of the Liver (AISF), Coco B, Caraceni P, Aghemo A, Bitetto D, Bruno R, Ciancio A, Marziani M, Petta S, Rendina M, Valenti L. Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). *Dig Liver Dis.* 2014;46:18-24

53. Ciancio A, Rizzetto M. Chronic hepatitis D at a standstill: where do we go from here? *Nat Rev Gastroenterol Hepatol.* 2014;11:68-71.

54. Giordanino C, Sacco M, Ceretto S, Smedile A, Ciancio A, Cariti G, De Blasi T, Picciotto A, Marengo S, Grasso A, Pirisi M, Smirne C, Colletta C, Traverso A, Mazzucco D, Ciccone G, Simondi D, Rizzetto M, Saracco G. Durability of the response to peginterferon- α 2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting. *Eur J Gastroenterol Hepatol.* 2014;26:52-8.

55. Craxì A, Piccinino F, Ciancio A, Iannacone C, Deodato B, Golotta C, Ascione A. Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study. *Eur J Gastroenterol Hepatol.* 2014;26:388-95

56. De Nicolò A, Boglione L, Ciancio A, Cusato J, Strona S, Cardellino CS, Abdi AM, Cariti G, Troshina G, Caviglia GP, Smedile A, Rizzetto M, Di Perri G, D'Avolio A. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. *Antiviral Res.* 2014;109:7-14.

57. Rosina F, Tosti ME, Borghesio E, Masocco M, Mele A, Coppola C, Milella M, Borgia G, Andreone P, Koch M, Zignego AL, Romano M, Carrara M, Almasio PL, Azzola E, Nardone G, Benedetti A, Carosi G, Mazzotta F, Sagnelli E, Rizzetto M. Pegylated interferon α . plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency. *Dig Liver Dis.* 2014;46:826-32.

58. Rosso C, Abate ML, Ciancio A, Strona S, Caviglia GP, Olivero A, Touscoz GA, Rizzetto M, Pellicano R, Smedile A. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. *World J Gastroenterol.* 2014; 20:13146-52

59. Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M, Ciancio A, Brancaccio G, Forte P, Carretta V, Zignego AL, Minerva N, Brindicci G, Marignani M, Baroni GS, Bertino G, Cuccorese G, Mottola L, Ripoli M, Pirisi M. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. *PLoS One.* 2014; 23;9(10):e110284. doi: 10.1371/journal.pone.0110284

60. Bruno S, Bollani S, Zignego AL, Pascasio JM, Magni C, Ciancio A, Caremani M, Mangia A, Marengo S, Piovesan S, Chemello L, Babudieri S, Moretti A, Gea F, Colletta C, Perez-Alvarez R, Fornis X, Larrubia JR, Arenas J, Crespo J, Calvaruso V, Ceccherini Silberstein F, Maisonneuve P, Craxì A, Calleja JL; Italian and Spanish (IAS)-BoC Study Group. Undetectable HCV-RNA at treatment-week 8 results in high-sustained

virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. *J Viral Hepat.* 2014. doi: 10.1111/jvh.12342.

61. Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. *World J Gastroenterol.* 2014;20:16726-33.

62. Cusato J, Allegra S, De Nicolò A, Boglione L, Fatiguso G, Cariti G, Ciancio A, Smedile A, Strona S, Troshina G, Rizzetto M, Di Perri G, D'Avolio A. ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. *Biomed Pharmacother.* 2015;69:63-9.

63. Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, Ciancio A, Raffa G, Sangiovanni A, Navarra G, Raimondo G, Pollicino T. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. *Liver Int.* 2015; 35: 2311-7.

64. Caviglia GP, Sciacca C, Abate ML, Olivero A, Rosso C, Touscoz GA, Ciancio A, Rizzetto M, Smedile A. Chronic hepatitis C virus infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, and B-cell non-Hodgkin lymphoma. *J Gastroenterol Hepatol.* 2015;30:742-7

65. Coppo C, Bonfanti D, Bo S, Giordanino C, Gallo M, Cococcia S, Ciccone G, Smedile A, Ciancio A, Bugianesi E, Fagoonee S, Pellicano R, Rizzetto M, Saracco GM. Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study. *Dig. Liver Dis* 2015;47:405-10.

66. Rizzetto M, Ciancio A. The prenylation inhibitor, lonafarnib: a new therapeutic strategy against hepatitis delta. *Lancet Infect Dis.* 2015;15:1119-20.

67. Morisco F, Bruno R, Bugianesi, Burra P, Calvaruso V, Cannoni A, Caporaso N, Caviglia GP, Ciancio A et al. AISF position paper on liver disease and pregnancy. *Dig Liver Dis.* 2016;48:120-37

68. Craxì A, Perno CF, Viganò M, Ceccherini-Silberstein F, Petta S, Aghemo A, Alberti A, Andreoni M, Bonora S, Brunetto MR, Bruno S, Caporaso N, Chirianni A, Ciancio A et al. AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. From current status to optimization of HCV treatment: Recommendations from an expert panel. *Dig Liver Dis.* 2016;48:995-1005

69. Caviglia GP, Abate ML, Noviello D, Olivero A, Rosso C, Troshina G, Ciancio A, Rizzetto M, Saracco GM, Smedile A. Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon- α . *Hepatol Res.* 2017; 47:747-754.

70. Niro GA, Smedile A, Fontana R, Olivero A, Ciancio A, Valvano MR, Pittaluga F, Coppola N, Wedemeyer H, Zachou K, Marrone A, Fasano M, Lotti G, Andreone P, Iacobellis A, Andriulli A, Rizzetto M. HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. *Aliment Pharmacol Ther.* 2016;44:620-8

71. Cento V, Barbaliscia S, Lenci I, Ruggiero T, Magni CF, Paolucci S, Babudieri S, Siciliano M, Pasquazzi C, Ciancio A, Perno CF, Ceccherini-Silberstein F; HCV retreatment team VIRONET-C study group. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. *Clin Microbiol Infect.* 2017; 23: 777.e1-777.e4

72. Viganò M, Perno CF, Craxì A; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. *Dig Liver Dis.* 2017;49:731-741
73. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. *Lancet Gastroenterol Hepatol.* 2017;2:427-434.
74. Caviglia GP, Abate ML, Gaia S, Petrini E, Bosco C, Olivero A, Rosso C, Ciancio A, Pellicano R, Saracco GM, Rizzetto M, Smedile A. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR- 122, AFP and PIVKA-II. *Panminerva Med.* 2017; 59: 283-289
75. Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, Zignego AL, Ciancio A, Di Leo A, Raimondo G, Ferrari C, Taliani G, Borgia G, Santantonio TA, Blanc P, Gaeta GB, Gasbarrini A, Chessa L, Erne EM, Villa E, Ieluzzi D, Russo FP, Andreone P, Vinci M, Coppola C, Chemello L, Madonia S, Verucchi G, Persico M, Zuin M, Puoti M, Alberti A, Nardone G, Massari M, Montalto G, Foti G, Rumi MG, Quaranta MG, Cicchetti A, Craxì A, Vella S; PITER Collaborating Group. Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort. *Hepatology.* 2017; 66: 1814-25
76. Karampatou A, Han X, Kondili LA, Taliani G, Ciancio A, Morisco F, Critelli RM, Baraldi E, Bernabucci V, Troshina G, Guarino M, Tagliavini S, D'Ambrosio F, Bristot L, Turco L, Rosato S, Vella S, Trenti T, Neri I, La Marca A, Manthena S, Goldstein AS, Bruno S, Bao Y, Gonzalez YS, Villa E; PITER framework investigators; PITER Investigators. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. *J Hepatol.* 2017 pii: S0168-8278(17)32259-6. doi: 10.1016/j.jhep.2017.08.019
77. Di Maio VC, Cento V, Aragri M, Paolucci S, Pollicino T, Coppola N, Bruzzone B, Ghisetti V, Zazzi M, Brunetto M, Bertoli A, Barbaliscia S, Galli S, Gennari W, Baldanti F, Raimondo G, Perno CF, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? *J Hepatol.* 2018;68:597-600
78. Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E, Fassio G, Bianco Mauthe Degerfeld AGF, Gallo M, Giordanino C, Terzi di Bergamo L, Ribaldone D, Bugianesi E, Smedile A, Rizzetto M, Saracco GM. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. *J Med Virol.* 2018;90:320-327
79. Younes R, Rosso C, Petta S, Cucco M, Marietti M, Caviglia GP, Ciancio A, Abate ML, Cammà C, Smedile A, Craxì A, Saracco GM, Bugianesi E. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. *Liver Int.* 2018;38:715-723
80. Karampatou A, Han X, Kondili LA, Taliani G, Ciancio A, Morisco F, Critelli RM, Baraldi E, Bernabucci V, Troshina G, Guarino M, Tagliavini S, D'Ambrosio F, Bristot L, Turco L, Rosato S, Vella S, Trenti T, Neri I, La Marca A, Manthena S, Goldstein AS, Bruno S, Bao Y, Gonzalez YS, Villa E; PITER framework investigators. Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [*J Hepatol* 68 (2018) 33-41]. *J Hepatol.* 2018. pii: S0168-8278(18)30013-8. doi: 10.1016/j.jhep.2018.01.004. [Epub ahead of print]
81. Caviglia GP, Abate ML, Tandoi F, Ciancio A, Amoroso A, Salizzoni M, Saracco GM, Rizzetto M,

Romagnoli R, Smedile A. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. *J Hepatol.* 2018;69:301-307

82. Caviglia GP, Ribaldone DG, Abate ML, Ciancio A, Pellicano R, Smedile A, Saracco GM. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. *Scand J Gastroenterol.* 2018;53:734-740

83. Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, Ciancio A, Di Marco V, Lampertico P, Brunetto MR, Zuin M, Andreone P, Villa E, Troshina G, Calvaruso V, Degasperis E, Coco B, Giorgini A, Conti F, Di Leo A, Marzi L, Boccaccio V, Bollani S, Maisonneuve P, Bruno S. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. *Aliment Pharmacol Ther.* 2018;47:1705-1712

84. Ponzetto A, Figura N, Ciancio A. Containing the Costs of Recurrent Gastro-Duodenal Ulcer Bleeding. *Dig Dis.* 2018;36:269.

85. Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marziani M, Giannini EG, Craxi A; ABACUS Study Group. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. *Infection.* 2018;46:607-615

86. Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxi A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. *Sci Rep.* 2018;8:8988.

87. Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonna S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxi A; PITER Collaborating Group. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? *Liver Int.* 2018;38:2190-2198

88. Senore C, Giovo I, Ribaldone DG, Ciancio A, Cassoni P, Arrigoni A, Fracchia M, Silvani M, Segnan N, Saracco GM. Management of P11 tumours removed by endoscopy during colorectal cancer screening: Outcome and treatment quality indicators. *Eur J Surg Oncol.* 2018;44:1873-1879

89. Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group available at www.progettopiter.it. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. *Pharmacoeconomics*. 2018. doi: 10.1007/s40273-018-0733-3. [Epub ahead of print]

90. Ponzetto A, Ciancio A, Figura N. Delta hepatitis in resolved hepatitis B. *Eur J Gastroenterol Hepatol.* 2018;30:1528. doi: 10.1097/MEG.0000000000001253

91. Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, Persico M; collaborators. Predictors of

hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. *Dig Liver Dis.* 2018; 31. pii: S1590-8658(18)31210-6

92. Viganò M, Andreoni M, Perno CF, Craxi A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Faggioli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL. Real life experiences in HCV management in 2018. *Expert Rev Anti Infect Ther.* 2019;17:117-128. doi: 10.1080/14787210.2019.1563755. Epub 2019 Jan 15. PMID: 30582384

93. Mangia A, Cenderello G, Copetti M, Verucchi G, Piazzolla V, Lorusso C, Santoro R, Squillante MM, Orlandini A, Minisini R, Ciancio A. SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. *Cells.* 2019;8:313. doi: 10.3390/cells8040313. PMID: 30987413

94. Rosso C, Caviglia GP, Ciruolo M, Ciancio A, Younes R, Olivero A, Giordanino C, Troshina G, Abate ML, Rizzetto M, Pellicano R, Saracco GM, Bugianesi E, Smedile A. Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. *Minerva Med.* 2019;110:401-409. doi: 10.23736/S0026-4806.19.06108-1. Epub 2019 May 6.

95. Ponzetto A, Riva P, Ciancio A. Addition of Bismuth to the Standard Triple Therapy for Helicobacter Pylori Infection. *Clin Gastroenterol Hepatol.* 2019;17:2822. doi: 10.1016/j.cgh.2019.05.036. PMID: 31757364

96. Caviglia GP, Olivero A, Ciancio A, Tandoi F, Troshina G, Rosso C, Abate ML, Younes R, Ribaldone DG, Smedile A, Rizzetto M, Romagnoli R, Saracco GM, Bugianesi E. Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. *Diagn Microbiol Infect Dis.* 2020; 96:114985. doi: 10.1016/j.diagmicrobio.2020.114985. Epub 2020 Jan 9. PMID: 32008810

97. Stroffolini T, Ciancio A, Furlan C, Vinci M, Fontana R, Russello M, Colloredo G, Morisco F, Coppola N, Babudieri S, Ferrigno L, Sagnelli C, Sagnelli E. Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium. *J Viral Hepat.* 2020. doi: 10.1111/jvh.13310. Online ahead of print. PMID: 32338810

98. Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder SD, Zoulim F, Botros I, Flaherty JF, Jump B, Op den Brouw ML, van Troostenburg A, Ramroth H; ReCoRd (Retrospective, Cohort, Renal, Viread) Investigators' Group. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. *Aliment Pharmacol Ther.* 2020. doi: 10.1111/apt.15901. Online ahead of print. PMID: 32583915

99. Marinucci C, Zardo F, Diella F, Cocito D, Ciancio A, Porta M, Zanone MM. A deceiving case of paraplegia.. *Intern Emerg Med.* 2020;15:473-478. doi: 10.1007/s11739-019-02059-7. PMID: 30815781

100. Caviglia GP, Ciruolo M, Abate ML, Carucci P, Rolle E, Rosso C, Olivero A, Troshina G, Risso A, Nicolosi A, Ribaldone DG, Armandi A, Tandoi F, Saracco GM, Bugianesi E, Ciancio A, Gaia S. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. *Cancers (Basel).* 2020; 12:3218 - doi: 10.3390/cancers12113218. PMID: 33142893; PMCID: PMC7692611.

101. Stroffolini T, Lombardi A, Ciancio A, Fontana R, Colloredo G, Marignani M, Vinci M, Morisco F, Babudieri S, Ferrigno L, Sagnelli E. Hepatitis B vaccine coverage and risk factors for lack of vaccination in subjects with HBsAg negative liver cirrhosis in Italy: still, much work should be done. *Dig Liver Dis.* 2021 Oct;53(10):1315-1319. doi: 10.1016/j.dld.2020.10.011. Epub 2020 Nov 6. PMID: 33162352.
102. Mangia A, Cenderello G, Verucchi G, Ciancio A, Fontana A, Piazzolla V, Minerva N, Squillante MM, Copetti M. Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis? *World J Clin Cases.* 2020;8(22):5831-5834
103. Stroffolini T, Lombardi A, Ciancio A, Niro GA, Colloredo G, Marignani M, Vinci M, Morisco F, Babudieri S, Ferrigno L, Sagnelli E. Low influenza vaccination coverage in subjects with liver cirrhosis. An alert waiting for winter season 2020-2021 during the COVID-19 pandemic. *J Med Virol.* 2021 Apr;93(4):2446-2452. doi: 10.1002/jmv.26763. Epub 2021 Jan 11. PMID: 33368427
104. Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. *Liver Int.* 2021. doi: 10.1111/liv.14797.
105. Ciancio A, Ribaldone DG, Dotta A, Giordanino C, Sacco M, Fagoonee S, Pellicano R, Saracco GM. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents. *Liver Int.* 2021;41(2):276-287
106. Stroffolini T, Ciancio A, Furlan C, Vinci M, Niro GA, Russello M, Colloredo G, Morisco F, Coppola N, Babudieri S, Ferrigno L, Sagnelli C, Sagnelli E; Collaborating group. Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019. *Eur J Clin Microbiol Infect Dis.* 2021;40:607-614.
107. Aghemo A, Alberti A, Andreone P, Angelico M, Brunetto MR, Chessa L, Ciancio A, Craxì A, Gaeta GB, Galli M, Gasbarrini A, Giorgini A, Grilli E, Lampertico P, Lichtner M, Milella M, Morisco F, Persico M, Pirisi M, Puoti M, Raimondo G, Romano A, Russello M, Sangiovanni V, Schiavini M, Serviddio G, Villa E, Vinci M, De Michina A, Gallinaro V, Gualberti G, Roscini AS, Zignego AL; MARS Study Group. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. *Dig Liver Dis.* 2021;53:612-619. doi: 10.1016/j.dld.2020.08.007. PMID: 32917546
108. Caviglia GP, Troshina Y, Garro E, Gesualdo M, Aneli S, Birolo G, Pittaluga F, Cavallo R, Saracco GM, Ciancio A. Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study. *J Clin Med.* 2021 27;10:3308. doi: 10.3390/jcm10153308. PMID: 34362093

109. Zanone MM, Marinucci C, Ciancio A, Cocito D, Zardo F, Spagone E, Ferrero B, Cerruti C, Charrier L, Cavallo F, Saracco GM, Porta M. Peripheral neuropathy after viral eradication with direct-acting antivirals in chronic HCV hepatitis: A prospective study. *Liver Int.* 2021. doi: 10.1111/liv.15002. Online ahead of print. PMID: 34219359
110. Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Coppola C, Ciancio A, Bruno SR, Loi M, Giorgini A, Margotti M, Cossiga V, Brancaccio G, Dallio M, De Siena M, Cannizzaro M, Cavalletto L, Massari M, Mazzitelli M, De Leo P, Laccabue D, Baiocchi L, Kondili LA. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. *BMC Infect Dis.* 2021 ;21:413. doi: 10.1186/s12879-021-06053-3. PMID: 33947337
111. Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Massari M, Coppola C, Biliotti E, Giorgini A, Laccabue D, Ciancio A, Blanc PL, Margotti M, Ieluzzi D, Brunetto MR, Barbaro F, Russo FP, Beretta I, Morsica G, Verucchi G, Saracino A, Galli M, Kondili LA; PITER Collaborating Group. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. *Dig Liver Dis.* 2021; 20:S1590-8658(21)00137-7. doi: 10.1016/j.dld.2021.03.020. Online ahead of print. PMID: 33893040
112. Caviglia GP, Abate ML, Rolle E, Carucci P, Armandi A, Rosso C, Olivero A, Ribaldone DG, Tandoi F, Saracco GM, Ciancio A, Bugianesi E, Gaia S. The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. *Biology (Basel).* 2021;10:215. doi: 10.3390/biology10030215. PMID: 33799723
113. Ciancio A. Impact of Direct Antiviral Agents (DAAs) on B-cell Non Hodgkin's Lymphoma in patients with chronic hepatitis C. *Minerva Gastroenterol (Torino).* 2021 Sep;67(3):227-233. doi: 10.23736/S2724-5985.21.02834-8. Epub 2021 Apr 15. PMID: 33856146.
114. Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxi A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. *Liver Int.* 2021;41:1802-1814. doi: 10.1111/liv.14797. Epub 2021 Feb 8. PMID: 33497016
115. Ciancio A, Ribaldone DG, Sacco M, Saracco GM. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C. *Liver Int.* 2021 Mar;41(3):640. doi: 10.1111/liv.14738. Epub 2020 Dec 2. PMID: 33222363.
116. Caviglia GP, Martini S, Ciancio A, Niro GA, Olivero A, Fontana R, Tandoi F, Rosso C, Romagnoli R, Saracco GM, Smedile A, Rizzetto M. The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. *J Adv Res.* 2021 Mar 2;33:183-187. doi: 10.1016/j.jare.2021.02.009. PMID: 34603788; PMCID: PMC8463926.
117. Kondili LA, Monti M, Quaranta MG, Gragnani L, Panetta V, Brancaccio G, Mazzaro C, Persico M, Masarone M, Gentile I, Andreone P, Madonna S, Biliotti E, Filomia R, Puoti M, Fracanzani AL, Laccabue D, Ieluzzi D, Coppola C, Rumi MG, Benedetti A, Verucchi G, Coco B, Chemello L, Iannone A, Ciancio A, Russo FP, Barbaro F, Morisco F, Chessa L, Massari M, Blanc P, Zignego AL. A

prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. *Hepatology*. 2021 Dec 16. doi: 10.1002/hep.32281. Epub ahead of print. PMID: 34919289.

118. Ciancio A, Ribaldone DG, Salamone R, Bruno M, Caronna S, Debernardi Venon W, Giordanino C, Mondardini A, Musso A, Pennazio M, Rolle E, Sacco M, Sprujevnik T, De Angelis C, Saracco GM. Screening and surveillance of oesophageal varices in patients with HCV-positive liver cirrhosis successfully treated by direct-acting antiviral agents. *Liver Int*. 2022 Feb 26. doi: 10.1111/liv.15210. Epub ahead of print. PMID: 35220668.

119. Caviglia GP, Troshina G, Santaniello U, Rosati G, Bombaci F, Birolo G, Nicolosi A, Saracco GM, Ciancio A. Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. *Cancers (Basel)*. 2022 Feb 6;14(3):828. doi: 10.3390/cancers14030828. PMID: 35159094; PMCID: PMC8834182.

120. Cusato J, Boglione L, De Nicolò A, Caviglia GP, Mornese Pinna S, Ciancio A, Troshina G, Smedile A, Antonucci M, Avataneo V, Palermi A, Mula J, Manca A, Cariti G, Cantù M, Saracco GM, Di Perri G, D'Avolio A. Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy. *Pharmaceuticals (Basel)*. 2022 Mar 15;15(3):355. doi: 10.3390/ph15030355. PMID: 35337152; PMCID: PMC8953593.

BOOKS

1. Smedile A, Ciancio A and Rizzetto M. Hepatitis D virus. In *Clinical Virology 2002* Eds: Douglas D. Richman, Richard J. Whitley and Frederick G. Hayden.
2. Smedile A, Ciancio A and Rizzetto M. Hepatitis D virus. In *Clinical Virology 2009* Eds: Douglas D. Richman, Richard J. Whitley and Frederick G. Hayden. 3rd edition. Washington DC, pp 1291-1306
3. Ciancio A, Rizzetto M. Chapter 29. Treatment of Hepatitis D - In *Viral Hepatitis* a cura di H.C. Thomas, A.S.F. Lok, S.A. Locarnini, A.J Zuckerman Ed. Wiley Blackwell (quarta edizione)
4. Ciancio A and Rizzetto M. Clinical patterns, epidemiology and disease burden of hepatitis D virus chronic liver disease. *Viral Hepatitis and Liver Disease: Proceedings of 10th International Symposium on Viral hepatitis and Liver Disease*. Eds.H.Margolis, M.Alter, T.Liang, J.Dienstang. International Medical Press pp271-275, 2002
5. Ciancio A., Alberti A. Capitolo “La terapia dell’epatite C “ In *Manuale UniGastro 2013-2015*” – Il Pensiero Scientifico Editore
6. Ciancio A. , Alberti A. Capitolo 27. “La terapia dell’epatite virale cronica” In *Manuale UniGastro 2016-2019*” – Il Pensiero Scientifico Editore

7. Ciancio A, DiMarco V. Capitolo 30. “Epatiti Virali” In Manuale UniGastro 2020. – Il Pensiero Scientifico Editore
8. Ciancio A, DiMarco V. Chapter 30. “Viral Hepatitis” In Manuale UniGastro 2020 versione in inglese. – Il Pensiero Scientifico Editore
9. Ciancio A. Chapter “ Drug to drug interactions with direct acting antiviral”. In The Treatment of Hepatitis C – Mangia A. 2017 Ed. Minerva Medica
10. Ciancio A, Rizzetto M. Chronic viral hepatitis. In Hepatology at Bedside: Antonio Ascione, 2003 ; chapter 27 pp115-139
11. Ciancio A, Paganin S, Lavezzo B, A.Smedile: Liver transplantation for viral cirrhosis. In Hepatology at Bedside: Antonio Ascione, 2003 ; chapter 27 pp567-585
12. Ciancio A., Smedile A. “Epatite cronica: storia naturale e diagnosi”. Educazione permanente. Malattie digestive Ott. Dic. '97 Cap. 12 p 3-8. Il Pensiero Scientifico Editore.
13. Translation of some chapter in Sleisenger e Fordtran. Edizioni Edra SpA 2018

RECOGNITIONS

1. November 1998: winner of award for young Investigators, from the Italian Association for the Study of Liver Disease (AISF)
2. Winner of grant for young investigator in clinical research from Rotary Club Torino Nord Ovest. Torino January 25, 2001
3. October 2003: grant from “Compagnia San Paolo” for clinical research
4. Winner of grant in clinical research from Ministero della Salute – Ricerca Sanitaria Finalizzata. Anno 2007
5. Winner of grant in clinical research – Fellowship Program 2016 with the project “Management optimization of patients with chronic HCV infection based on severity of liver disease.”
6. Winner of grant in clinical research – Fellowship Program 2018 with the project “Screening of viral hepatitis and treatment in difficult to rich patients (SerD, jail and family counseling)
7. April 2020: Grant in clinical research for the project “FROM GLOBAL TESTING IN EMERGENCY DEPARTMENTS TO TREATMENT “
8. Winner of grant in clinical research – Fellowship Program 2022 with the project “NETWORK Delta piemontese-valdostano per la diagnosi e il management dei pazienti affetti da epatopatia da virus HDV”

For the processing of ordinary personal data in compliance with Italian Legislative Decree 196/2003, I undersigned, authorize the processing of my personal data hereby transmitted

Date _____ Signature _____

